InhibrxINBX
INBX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
206% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $418K
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
23% more capital invested
Capital invested by funds: $139M [Q3] → $172M (+$32.5M) [Q4]
15.6% more ownership
Funds ownership: 61.48% [Q3] → 77.09% (+15.6%) [Q4]
4% more funds holding
Funds holding: 96 [Q3] → 100 (+4) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 30
Research analyst outlook
We haven’t received any recent analyst ratings for INBX.
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
Neutral
PRNewsWire
2 months ago
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). These results were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Annual Cancers Symposium.
Neutral
PRNewsWire
2 months ago
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security agreement (the "LSA") with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders provided a five-year term loan facility for up to $150 million (the "Credit Facility"). "This enables us strategic flexibility post data readouts expected later this year for our INBRX-109 and INBRX-106 programs," said Kelly Deck, Chief Financial Officer of Inhibrx.
Neutral
PRNewsWire
4 months ago
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
Positive
Seeking Alpha
4 months ago
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025.
Neutral
PRNewsWire
4 months ago
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical standards and innovation in scientific research.
Positive
Benzinga
7 months ago
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades.
Neutral
InvestorPlace
7 months ago
INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
Inhibrx (NASDAQ: INBX ) just reported results for the first quarter of 2024. Inhibrx reported earnings per share of -$1.44.
Neutral
PRNewsWire
7 months ago
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
Positive
Seeking Alpha
9 months ago
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
Charts implemented using Lightweight Charts™